The use of low-dose L-deprenyl, a selective MAO-B inhibitor, in Alzheimer's disease patients has been associated previ ously with improvements in agitation and episodic learning and memory. Behavioral, cognitive, and regional electroen cephalogram (EEG) measures were obtained in a 4-week open pilot study of 14 patients with probable Alzheimer's disease by NINCDS criteria who were administered 10 mg L-deprenyl per day. L-Deprenyl administration was associated with significant improvements on the agitation and depression factors of the Brief Psychiatric Rating Scale, the Cornell Scale for Depression in Dementia, and spouses' blind ratings. Recall improved on the Buschke Selective Reminding Task, but intrusions also tended to increase; verbal fluency decreased. Absolute EEG delta measures were selectively sup pressed in the right frontal region. The pattern of changes suggests that L-deprenyl may be associated with improvement in behavioral and cognitive performance, in part through a mild behavioral disinhibiting effect. (J Geriatr Psychiatry Neurol 1991;4:143-148).
Get full access to this article
View all access options for this article.
References
1.
Tariot PN, Cohen RM, Sunderland T., et al: L-Deprenyl in Alzheimer's disease: Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry1987;44:427-433.
2.
Martini E., Pataky I., Szilagyi K., Venter V.: Brief information on an early phase-II study with deprenyl in demented patients . Pharmacopsychiatry1987;20:256-257.
3.
Tariot PN, Sunderland T., Weingartner H., et al: Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology1987;91:489-495.
4.
Piccinin GL, Finali G., Piccirilli M.: Neuropsychological effects of L-deprenyl in Alzheimer's type dementia . Clin Neuropharmacol1990;13:147-163.
5.
Quitkin FM, Liebowitz MR, Stewart JW, et al: L-Deprenyl in atypical depressives. Arch Gen Psychiatry1984;41:777-781.
6.
Mann JJ, Frances A., Kaplan RD, et al: The relative efficacy of L-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol1982;2:54-57.
7.
Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med1989;321:1364-1371.
8.
Levitt P., Pintar JE, Breakefield XO: Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA1982;79:6385.
9.
Sunderland T. , Tariot PN, Cohen RM, et al: Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology1987;91:293-296.
10.
Adolfsson R. , Gottfries CG, Oreland L., et al: Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci1980;27:1029.
11.
Alexopoulos GS, Lieberman KW, Young RC: Platelet MAO activity in primary degenerative dementia. Am J Psychiatry1984;141:97.
12.
Alexopoulos GS , Liberman KW, Young RC, Shamoian CA: Monoamines and monoamine oxidase in primary degenerative dementia, in Shamoian CA (ed): Biology and Treatment of Dementia in the Elderly. Washington, DC, American Psychiatric Press, 1984, pp 60-71.
13.
Schneider LS , Severson JA, Chui H., et al: Platelet tritiated imipramine binding and MAO activity in Alzheimer's patients with agitation and delusions. Psychiatry Res1988;25:311- 322.
14.
McKhann G., Drachman D., Folstein M., et al: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group. Neurology1984;34:939-944.
15.
Overall JE, Beller SA: The brief psychiatric rating scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol1984;39:187-193.
16.
Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell scale for depression in dementia . Biol Psychiatry1988;23:271-284.
17.
Raskin A.: Validation of a battery of tests designed to assess psychopathology in the elderly, in Burrows GD, Norman TR, Dennerstein L , et al (eds): Clinical and Pharmacological Studies in Psychiatric Disorders. London, John Libbey, 1985, pp 337-343.
18.
Buschke H., Fuld PA: Evaluating storage, retention, and retrieval in disordered memory and learning . Neurology1974;24:1019-1025.
19.
Benton AL, Hamsher K.: Multilingual Aphasia Examination, revised. Iowa City, IA , University of Iowa, 1978 .
20.
Lewis RF, Rennick PM: Manual for the Lafayette Repeatable Cognitive-Perceptual-Motor Battery . Grosse Pointe Park, MI, Axon , 1979 .
21.
Wechsler D.: WAIS-R Manual. New York, Psychological Corp, 1981.
22.
Schneider LS , Severson JA, Pollock VE, et al: Platelet monoamine oxidase activity in elderly depressed outpatients. Biol Psychiatry1986;21:1360-1364.
23.
Pollock VE, Schneider LS: Topographic quantitative EEG in elderly subjects with major depression . Psychophysiology1990;27:438-444.
24.
Pollock VE, Schneider LS, Lyness SA: EEG amplitudes in healthy late-middle-aged and elderly adults: Normality of the distributions and correlations with age. Electroencephalogr Clin Neurophysiol1990;75:276-288.
25.
Herrmann WM, Schaerer E.: Pharmaco-EEG: Computer analysis to describe the projection of drug effect on a functional cerebral level in humans, in Lopes da Silva FH, Storm van Leeuwen W , Remond A (eds): Handbook of Electroencephalography and Clinical Neurophysiology, Vol 2. 1986, Amsterdam, Elsevier, pp 385-448.
26.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry1984;141:1356-1364.
27.
Sunderland T., Molchan SE, Lalonde FM, et al: Combination pharmacotherapy in Alzheimer's disease: Deprenyl plus physostigmine (abstract). Am CollNeuropsychopharmacol, 1989.
